-+ 0.00%
-+ 0.00%
-+ 0.00%

INmune Bio Targets UK Ebstrocel Approval in Mid-2027

PUBT·10/21/2026 11:15:31
Listen to the news
INmune Bio Targets UK Ebstrocel Approval in Mid-2027
  • INmune Bio targets an early February 2027 UK approval application for Ebstrocel, its investigational therapy for recessive dystrophic epidermolysis bullosa.
  • Potential UK approval in mid-2027 could come approximately six weeks earlier under the revised submission strategy.
  • A US biologics license application is planned for the second quarter of 2027, subject to FDA meeting feedback.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610210715PRIMZONEFULLFEED9849919) on October 21, 2026, and is solely responsible for the information contained therein.